BioNexus Gene Lab creates Series Z Preferred with 5B votes to facilitate Reverse Stock Split

BioNexus Gene Lab Corp

Created one share of Series Z Preferred Stock with 5,000,000,000 votes, solely on Reverse Stock Split matter.
Issued to director Muhammad Azrul bin Abdul Hamid on Feb 10, 2025, exempt under Section 4(a)(2).
Series Z will vote proportionally to common shares, increasing total votes but not affecting percentage for/against.
Purpose is to ensure passage of Reverse Stock Split at upcoming Special Meeting.
Share may be cancelled by Board or automatically upon shareholder approval of Reverse Split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BioNexus Gene Lab Corp: Filed Articles of Amendment to authorize creation of Series Z Convertible Preferred Stock with special voting rights tied to a Reverse Stock Split proposal (effective 2025-02-11).

Change: charter amendment
Effective: 2025-02-11

Exact text from the filing

On February 11, 2025, the Company filed with the Wyoming Secretary of State Articles of Amendment to its Articles of Incorporation (a true and correct copy of which is attached hereto as Exhibit 3.6) (“Amendment”). The Amendment authorizes the creation of one (1) share of the Series Z Convertible Preferred Stock.

View on SEC.gov

Browse all governance changes →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-001063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.